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Purpose.E ﬀective Helicobacter pylori eradication requires delivery of the antibiotic locally in the stomach. High dose of amoxicillin
(750 to 1000mg) is diﬃcult to incorporate in ﬂoating tablets but can easily be given in liquid dosage form. Keeping the above
facts in mind, we made an attempt to develop a new ﬂoating in situ gelling system of amoxicillin with increased residence time
using sodium alginate as gelling polymer to eradicate H. pylori. Methods. Floating in situ gelling formulations were prepared using
sodium alginate, calcium chloride, sodium citrate, hydroxypropyl methyl cellulose K100, and sodium bicarbonate. The prepared
formulations were evaluated for solution viscosity, ﬂoating lag time, total ﬂoating time, and in vitro drug release. The formulation
was optimized using a 32 full factorial design. Dissolution data were ﬁtted to various models to ascertain kinetic of drug release.
Regression analysis and analysis of variance were performed for dependent variables. Results. All formulations (F1–F9) showed
ﬂoating within 30s and had total ﬂoating time of more than 24h. All the formulations showed good pourability. It was observed
that concentration of sodium alginate and HPMC K100 had signiﬁcant inﬂuence on ﬂoating lag time, cumulative percentage drug
release in 6h and 10h. The batch F8 was considered optimum since it showed more similarity in drug release (f2 = 74.38) to the
theoretical release proﬁle. Conclusion. Floating in situ gelling system of amoxicillin can be formulated using sodium alginate as a
gelling polymer to sustain the drug release for 10 to 12h with zero-order release kinetics.
1.Introduction
Helicobacter pylori (H. pylori) is one of the most common
pathogenic bacterial infections. It is associated with the
development of serious gastroduodenal disease, including
peptic ulcers, gastric lymphoma, and acute chronic gastritis.
H. pylori resides mainly in the gastric mucosa or at the
interface between the mucous layer and the epithelial cells
of the antral region of the stomach. Antibiotics required
for eradication of H. pylori are high in dose and in more
frequencies [1]. This is because of the low concentration
of the antibiotic reaching the bacteria under the mucosa,
instabilityofthedruginthelowpHofgastricﬂuid,andshort
residence time of the antibiotic in the stomach, leading to
incomplete eradication of H. pylori.
Amoxicillin is a semisynthetic, orally absorbed, broad-
spectrum antibiotic. It is widely used in a standard eradica-
tion treatment of gastric H. pylori infection combined with
a second antibiotic and an acid-suppressing agent [2]. As
conventional drug delivery systems do not remain in the
stomach for prolonged periods, they are unable to deliver the
amoxicillintothesiteofinfectionineﬀectiveconcentrations.
Therefore, it is necessary to design drug delivery systems that
not only alleviate the shortcomings of conventional delivery
vehicles but also deliver amoxicillin to the infected cell lines.
Someresearchershadpreparedandreportednewamoxicillin
formulations, such as ﬂoating tablets [3, 4], mucoadhesive
tablets [5], and mucoadhesive microspheres [6], which
were able to reside in stomach for an extended period for
more eﬀective H. pylori eradication. Amongst the described
formulations, the ﬂoating tablet is preferred for better and
less variable gastric retention, but it has a limitation of
incorporation of high dose of the drug. The drug with high
dose like amoxicillin can be easily incorporated in liquid in
situ gelling formulation that upon oral administration can
ﬂoat for a prolonged period of time in the stomach.2 ISRN Pharmaceutics
Table 1: Formulation of amoxicillin in situ gel using diﬀerent
concentrations of calcium chloride and sodium citrate.
Name of
ingredient
Quantity in 100mL (% w/v)
I-1 I-2 I-3
Amoxicillin 7.5 7.5 7.5
Calcium
chloride 0.075 0.10 0.15
Sodium citrate 0.25 0.33 0.5
Sodium alginate 2.5 2.5 2.5
HPMC K100 0.8 0.8 0.8
Sodium
bicarbonate 1.5 1.5 1.5
Deionised water Q.S Q.S Q.S
Gelling strength Open
network gel
Open
network gel
Close network
Stiﬀ gel
CPR 100 (in 3h) 100 (in 5h) 70.14 (in 6h)
CPRindicatescumulativepercentagerelease;HPMCK100indicateshydrox-
ypropyl methyl cellulose K100; Q.S indicates quantity suﬃcient.
Keeping the above facts in mind, we made an attempt to
develop a new ﬂoating in situ gelling system of amoxicillin
with increased residence time using sodium alginate as
gelling polymer [7] and hydroxypropyl methyl cellulose
K100 (HPMC K100) as thickening agent [8] with a potential
of H. Pylori eradication. The proposed new sodium alginate-
based amoxicillin ﬂoating in situ gelling systems would have
theadvantageofeaseofadministration,asbeingaliquid,and
also be more patient compliant.
2.MaterialsandMethods
2.1. Materials. Amoxicillin and hydroxypropyl methylcel-
lulose K100 (HPMC K100) were purchased from Yarrow
Chem. Products, Mumbai, India. Sodium alginate was
obtained from Finar Chemicals Pvt. Ltd, Ahmedabad, India.
Sodium bicarbonate was obtained from Shakti Chemicals,
Mehsana, India. Calcium chloride and sodium alginate
were obtained from Chemdyes Corporation, Ahmedabad,
India. All other materials and chemicals used were of either
pharmaceutical or analytical grade.
2.2. Methods
2.2.1. Preparation of In Situ Gelling Solution. Sodium algi-
nate, at diﬀerent concentrations (2%w/v, 2.5%w/v, and
3%w/v),waspreparedindeionisedwatercontainingcalcium
chloride (0.15%w/v) and sodium citrate (0.5%w/v). HPMC
K100 (0.3%w/v, 0.6%w/v, and 0.9%w/v) was added to
it. The sodium alginate solution was heated to 50◦Cw i t h
stirring. After cooling below 40◦C, 1.5%w/v of calcium
carbonate and drug were added and dispersed well with
continuous stirring. The resulting sodium alginate in situ gel
solution containing amoxicillin was ﬁnally stored in amber
colour narrow mouth bottles until further use.
2.2.2. Measurement of Viscosity of In Situ Gelling Solution.
The viscosities of the prepared solutions were determined
Table 2: Formulation of amoxicillin in situ gel using diﬀerent
concentrations of sodium bicarbonate.
Name of
ingredient
Quantity in 100mL (% w/v)
C-1 C-2 C-3
Amoxicillin 7.5 7.5 7.5
Calcium
chloride 0.15 0.15 0.15
Sodium citrate 0.5 0.5 0.5
Sodium alginate 2.5 2.5 2.5
HPMC K100 0.8 0.8 0.8
Sodium
bicarbonate 11 . 52
Deionised water Q.S Q.S Q.S
Floating lag
time (s) 55 48 30
CPR at 6h (%) 67.50 71.57 82.84
CPRindicatescumulativepercentagerelease;HPMCK100indicateshydrox-
ypropyl methyl cellulose K100; Q.S indicates quantity suﬃcient.
by brook ﬁeld viscometer (Brookﬁeld viscometer, model-
LVDV-II pro, USA). The samples (100mL) were sheared at
a rate of 100r/min using suitable spindle at room temper-
ature. Viscosity measurement for each sample was done in
triplicate, with each measurement taking approximately 30s.
2.2.3.InVitroGelationStudy. Gelationofinsitugellingsolu-
tion was carried out by taking 500mL of 0.1N hydrochloric
acid (HCl, pH 1.2) in a beaker. Accurately measured 10mL
of solution was added to HCl with mild agitation that avoids
breaking of formed gel. Gelling was observed visually by
qualitative measurement.
2.2.4. In Vitro Floating Study. Floating study of in situ gelling
solution was carried out in 500mL of 0.1N HCl (pH 1.2) in
a beaker. Accurately measured 10mL of solution was added
to HCl with mild agitation. Time required for ﬂoating on
surface after adding solution (ﬂoating lag time) and total
ﬂoating time were measured [9, 10].
2.2.5. In Vitro Drug Release Study. The in vitro release rate of
amoxicillin from sustained release in situ gel was performed
using USP apparatus [11] (model TDT-08T, Electrolab,
Mumbai, India) ﬁtted with paddle (50r/min) at 37 ± 0.5◦C
using 500mL of 0.1N HCl as a dissolution medium. This
speed was slow enough to avoid the breaking of gelled
formulation and was maintaining the mild agitation con-
ditions believed to exist in vivo. At the predetermined time
intervals, 10mL samples were withdrawn, ﬁltered through
a0 . 4 5μm membrane ﬁlter, diluted, and assayed at 272nm
using a Shimadzu UV 1800 double-beam spectrophotometer
(Shimadzu, Kyoto, Japan). Cumulative percentage drug
release (CPR) was calculated using an equation obtained
from a calibration curve.
2.2.6. Preliminary Screening. The preliminary screening was
performed to optimize amount of calcium chloride and
sodium bicarbonate in the formulation. For optimizationISRN Pharmaceutics 3
Table 3: Formulation and evaluation of batches in 32 full factorial design.
Batch code
Variable levels in coded form
FLT (s) Q1 (%) Q6 (%) Q10 (%) f2 Viscosity (cps)
X1 X2
F1 −1 −1 18 48.39 85.04 100.24 42.78 171.1
F2 −1 0 15 47.41 82.82 100.37 45.51 186.3
F3 −1 1 13 44.92 80.57 99.93 47.86 193.7
F4 0 −1 21 44.92 80.57 99.93 48.01 211.3
F5 0 0 15 44.21 79.16 98.80 51.11 230.4
F6 0 1 10 41.99 77.55 98.61 54.48 356.7
F7 1 −1 16 43.23 78.55 97.55 52.88 431.9
F8 1 0 12 42.88 67.03 85.02 74.38 542.1
F9 1 1 11 41.90 65.99 83.97 70.18 634.3
Coded values Actual values
X1 X2
−12 % 0 . 3 %
0 2.5% 0.6%
13 % 0 . 9 %
All batches contained 7.5% of amoxicillin, 1.5% of sodium bicarbonate, 0.15% of calcium chloride, and 0.5% of sodium citrate. X1 indicates concentration of
sodium alginate, X2 concentration of HPMC K100. Q1, Q6,a n dQ10 indicate percentage drug released after 1, 6, and 10h, respectively. FLT indicates ﬂoating
lag time; f2 indicates similarity factor.
of amount of calcium chloride, in situ gelling systems of
amoxicillin were prepared using diﬀerent concentration of
calciumchlorideandproportionallysodiumcitrateasshown
in Table 1. Prepared in situ gelling systems were tested
for gelling strength and CPR at 6h. For optimization of
amount of sodium bicarbonate, in situ gelling systems of
amoxicillin were prepared using diﬀerent concentration of
sodium bicarbonate as shown in Table 2. Prepared in situ
gelling systems were tested for ﬂoating lag time (FLT) and
CPR at 6h.
2.2.7. Optimization of Variables Using Full Factorial Design.
A3 2 randomized full factorial design was used in the present
study.Inthisdesign,2factorswereevaluated,eachat3levels,
and experimental trials were performed for all 9 possible
combinations [12]. The concentration of sodium alginate
(X1) and concentration of HPMC K100 (X2) were chosen as
independent variables in 32 full factorial design, while FLT
(ﬂoating lag time), Q1, Q6,a n dQ10 (% drug release after 1, 6,
and 10 hours, resp.) were taken as dependent variables. The
formulation layout for the factorial design batches (F1–F9)i s
shown in Table 3.
2.2.8. Kinetic Modeling of Dissolution Data. The dissolution
proﬁle of all batches were ﬁtted to various models such as
zero order, ﬁrst order, Higuchi [13], Hixon and Crowell [14],
and Korsemeyer et al. [15], to ascertain the kinetic of drug
release. The method described by Korsemeyer et al. was used
to describe the mechanism of drug release.
2.2.9. Comparison of Release Proﬁles for Selection of Optimum
Batch. The similarity factor (f2) given by SUPAC guidelines
for a modiﬁed release dosage form was used as a basis to
Table 4: Summary of results of regression analysis.
b0 b1 b2 b12 b11 b22
For FLT
Response (FLT)
FM 14.77 −1.16 −3.5 −3.4∗10−16 −1.16 0.83
RM 14.56 — −3.5 — — —
For Q1
Response (Q1)
FM 44.11 −2.12 −1.29 0.53 1.09 −0.69
RM — — — — — —
For Q6
Response (Q6)
FM 77.95 −6.14 −3.34 −2.02 −2.42 1.70
RM 77.47 −6.14 — — — —
For Q10
Response (Q10)
FM 97.79 −5.66 −2.53 −3.31 −4.6 1.97
RM 96.04 −5.66 — — — —
FM= Full model, RM= Reduced model; Q1, Q6,a n dQ10 indicate percentage
of drug released after 1, 6, and 10h, respectively; FLT indicates ﬂoating lag
time.
compare dissolution proﬁles. The dissolution proﬁles are
considered to be similar when f2 is between 50 and 100. The
dissolution proﬁles of products were compared using an f2
which is calculated from the following formula:
f2 = 50 × log
⎧
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Table 5: Calculations for testing the model in portions.
DF SS MS FR 2
For ﬂoating lag time
Regression
FM 5 85.77 17.15 4.13 0.87
F calc. = 0.73
F table = 9.12
DF = (4,3)
RM 1 73.5 73.5 20.81 0.002
Error
FM 3 12.44 4.15
RM 7 24.72 3.53
For Q6
Regression
FM 5 327.42 65.48 8.71 0.935
F calc. = 3.36
F table = 9.12
DF = (4,3)
RM 1 226.44 226.44 12.83 0.64
Error
FM 3 22.54 7.51
RM 7 123.51 17.64
For Q10
Regression
FM 5 325.37 65.07 7.83 0.92
F calc. = 3.99
F table = 9.12
DF = (4,3)
RM 1 192.66 192.66 — 0.55
Error
FM 3 12.44 4.15
RM 7 24.72 3.53
DF indicates the degree of freedom; SS: Sum of squares; MS: Mean of squares; R2: Regression coeﬃc i e n t ;F M :F u l lm o d e l ;R M ,R e d u c e dm o d e l .Q6 and Q10
indicate percentage of drug released after 6 and 10h, respectively.
where n is the dissolution time, and Rt and Tt are the ref-
erence (here, this is the theoretical dissolution proﬁle of am-
oxicillin) and test dissolution value at time t [16].
2.2.10. Fourier Transform Infrared Spectroscopy. Fourier
transform infrared (FTIR) spectra of amoxicillin, a physical
mixture of amoxicillin-HPMC K100, and a physical mixture
of amoxicillin-sodium alginate were recorded using KBr
mixing method on FTIR instrument available at central
instrument laboratory of the institute (FTIR-1700, Shi-
madzu, Kyoto, Japan).
3. Results andDiscussion
3.1. Results of Preliminary Screening. Three batches (I-1,
I-2, and I-3) were prepared to optimize amount of cal-
cium chloride and proportionally sodium citrate. From the
observation of gelling strength and CPR at 6h of prepared
batches as shown in Table 1,i tw a sc o n c l u d e dt h a to n l yb a t c h
I-3 (containing 0.15%w/v of calcium chloride) formed the
closed network stiﬀ gel and controlled the release of drug for
more than 6h.
Three batches (C-1, C-2, and C-3) were prepared to
optimize amount of sodium bicarbonate (NaHCO3). From
the observation of ﬂoating lag time and CPR at 6h of
prepared batches as shown in Table 2, it was concluded that
batchC-2(containing1.5%NaHCO3)hadoptimumﬂoating
lag time (48s) and CPR at 6h (71.57).
3.2. Full Factorial Design. A statistical model incorporating
interactive and polynominal terms was used to evaluate the
responses
Y = b0 +b1X1 +b2X2 +b12X1X2 +b11X1X1 +b22X2X2,
(2)
where Y is the dependent variable, b0 is the arithmetic
mean response of the 9 runs, and b1 is the estimated
coeﬃcient for the factor Xi. The main eﬀects (X1 and
X2) represent the average result of changing 1 factor at a
time from its low to high values. The interaction terms
(X1X2) show how the response changes when two factors are
simultaneously changed. The polynomial terms (X2
1 and X2
2)
are included to investigate nonlinearity. The release proﬁle
for 9 batches showed a variation (i.e., initial 1hr release
rangingfrom41.90%to48.39%anddrugreleasedafter10hr
ranging from 83.97% to 100.37%). The data indicate that
the release proﬁle of the drug is strongly dependent on the
selectedindependent variables.Theﬁttedequations(fulland
reduced) relating the responses, FLT, Q1, Q6,a n dQ10, to the
transformed factor are shown in the Table 4.T h ep o l y n o m i a l
equations can be used to draw conclusions after considering
the magnitude of coeﬃcient and the mathematical sign it
carries (i.e., negative or positive). Table 4 shows the results
of analysis of variance (ANOVA), which was performed
to identify insigniﬁcant factors. Data were analyzed using
Microsoft Excel.ISRN Pharmaceutics 5
Table 6: Kinetic treatment of dissolution data.
F1 F2 F3 F4 F5 F6 F7 F8 F9
Zero order
b 5.17 5.27 5.42 5.45 5.44 5.89 5.78 4.59 4.42
a 47.48 45.72 43.66 43.52 42.24 37.46 38.33 40.13 40.10
R2 0.9619 0.9713 0.9716 0.9692 0.9771 0.9844 0.9811 0.9969 0.9941
First order
b 0.030 0.031 0.033 0.033 0.033 0.036 0.035 0.029 0.029
a 1.699 1.686 1.668 1.667 1.657 1.619 1.626 1.637 1.634
R2 0.9465 0.9554 0.9527 0.9496 0.9604 0.9702 0.9666 0.9874 0.9812
Higuchi
b 24.07 24.42 25.13 25.31 25.14 27.02 26.50 20.73 20.04
a 22.88 20.91 18.09 17.74 16.81 10.41 11.76 19.70 20.54
R2 0.9832 0.9880 0.9892 0.9877 0.9905 0.9893 0.9873 0.9897 0.9901
Hixon Crowell
b −0.09 −1.75 −1.80 −1.81 −1.83 −1.96 −1.92 −1.52 −1.47
a 0.973 18.09 18.77 18.82 19.25 20.84 20.55 19.95 19.97
R2 −0.9525 −0.9713 −0.9715 −0.9691 −0.9775 −0.9843 −0.9810 −0.9969 −0.9940
Korsemeyer and Peppas
n 0.333 0.341 0.361 0.364 0.363 0.396 0.387 0.316 0.313
a −0.34 −0.355 −0.376 −0.378 −0.385 −0.423 −0.416 −0.395 −0.399
R2 0.9845 0.9857 0.9885 0.9868 0.9877 0.9802 0.9756 0.9832 0.9859
b = slope, a = intercept, R2 = Square of correlation coeﬃcient, and n = diﬀusion exponent.
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Figure 1: Comparison of dissolution proﬁle.
R2 value for FLT, Q1, Q6,a n dQ10 is 0.87, 0.9956,
0.935, and 0.92, respectively, indicating good correlation
between dependent and independent variables. The reduced
models were developed for response variables by omitting
the insigniﬁcant terms with P>0.05. The terms with P<
0.05 were considered statistically signiﬁcant and retained in
the reduced model. The coeﬃcients for full and reduced
models for response variables are shown in Table 4.
3.3. Full and Reduced Model for FLT. The signiﬁcance levels
of the coeﬃcients b1, b12, b11,a n db22 were found to be P =
0.255, 1, 0.478, and 0.603, respectively, so they were omitted
from the full model to generate a reduced model. The results
of statistical analysis are shown in Table 4. The coeﬃcients b0
and b2 were found to be signiﬁcant at P<0.05; hence, they
were retained in the reduced model. The reduced model was
tested in proportion to determine whether the coeﬃcients
b1, b12, b11,a n db22 contribute signiﬁcance information to
the prediction of FLT [17]. The results of model testing are
shown in Table 5. The critical value of F for α = 0.05 is equal
to 9.12 (df = 4,3). Since the calculated value (F = 0.73) is
less than critical value (F = 9.12), it may be concluded that
the interaction terms b1, b12, b11,a n db22 do not contribute
signiﬁcantly to the prediction of FLT and can be omitted
from the full model to generate the reduced model.
3.4. Full and Reduced Model for Q6. The signiﬁcance levels
of the coeﬃcients b2, b12, b11,a n db22 were found to be
P = 0.058, 0.236, 0.291, and 0.443, respectively, so they
were omitted from the full model to generate a reduced
model. The results of statistical analysis are shown in Table 4.
The coeﬃcients b0 and b1 were found to be signiﬁcant at
P<0.05; hence, they were retained in the reduced model.
The reduced model was tested in proportion to determine
whether the coeﬃcients b2, b12, b11,a n db22 contribute
signiﬁcance information to the prediction of Q6. The results
of model testing are shown in Table 5. The critical value of F6 ISRN Pharmaceutics
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Figure 2: FTIR spectrum of amoxicillin.
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Figure 3: FTIR spectrum of amoxicillin and HPMC K100.
for α = 0.05 is equal to 9.12 (df = 4,3). Since the calculated
value (F = 3.36) is less than critical value (F = 9.12), it may
be concluded that the interaction terms b2, b12, b11,a n db22
do not contribute signiﬁcantly to the prediction of Q6 and
can be omitted from the full model to generate the reduced
model.
3.5. Full and Reduced Model for Q10. The signiﬁcance levels
of the coeﬃcients b2, b12, b11,a n db22 were found to be
P = 0.120, 0.104, 0.109, and 0.403, respectively, so they
were omitted from the full model to generate a reduced
model. The results of statistical analysis are shown in Table 4.
The coeﬃcients b0 and b1 were found to be signiﬁcant at
P<0.05; hence, they were retained in the reduced model.
The reduced model was tested in proportion to determine
whether the coeﬃcients b2, b12, b11,a n db22 contribute
signiﬁcance information to the prediction of Q10. The results
of model testing are shown in Table 5. The critical value of FISRN Pharmaceutics 7
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Figure 4: FTIR spectrum of amoxicillin and HPMC K100.
for α = 0.05 is equal to 9.12 (df = 4,3). Since the calculated
value (F = 3.99) is less than critical value (F = 9.12), it may
be concluded that the interaction terms b2, b12, b11,a n db22
do not contribute signiﬁcantly to the prediction of Q10 and
can be omitted from the full model to generate the reduced
model.
3.6. Kinetic Modeling of Dissolution Data. The kinetics of the
dissolution data were well ﬁtted to zero order, Higuchi mod-
el, and Korsemeyer-Peppas model as evident from regression
coeﬃcients (Table 6). In case of the controlled or sustained
release formulations, diﬀusion, swelling, and erosion are
the three most important rate controlling mechanisms.
Formulations containing swelling polymers show swelling as
well as diﬀusion mechanism because the kinetic of swelling
includes relaxation of polymer chains and imbibitions of
water, causing the polymer to swell and changing it from
a glassy to rubbery state. The diﬀusion exponent n is
the indicative of the mechanism of drug release from the
formulation. For a swellable cylindrical drug delivery system,
the n value of less than 0.45 is indicative of Fickian diﬀusion-
ontrolled drug release, n value between 0.45 and 0.89
signiﬁes anomalous (non-Fickian) transport, n value of 0.89
indicates case II transport, and n value greater than 0.85
indicates super case II transport [18, 19]. The value of
diﬀusion exponent n for all factorial formulations is less
than 0.45 (Table 6) indicating Fickian drug release from the
formulations.
3.7. Comparison of Release Proﬁles for Selection of Optimum
Batch. The release proﬁles of the developed formulations
are shown in Figure 1. The values of similarity factor (f2)
for batches F5 to F9 were greater than 50 compared with
theoreticalreleaseproﬁle(Table 3)indicatinggoodsimilarity
in dissolution. The batch F8 showed maximum value of f2
(74.38) and hence was selected as optimum batch.
3.8. Fourier Transform Infrared Spectroscopy. Drug-excipi-
ents interactions play a vital role in the release of drug from
formulation. Fourier transform infrared spectroscopy has
been used to study the physical and chemical interactions
between drug and the excipients used. The pure amoxicillin
and its mixture with sodium alginate and HPMC K100 were
mixed separately with IR grade KBr and were scanned over
a range of 400–4500cm−1 using FTIR instrument (FTIR-
1700, Shimadzu, Kyoto, Japan). The drug exhibits peak due
to ketonic, primary amine, secondary amine, and hydroxyl
(broad) group. It was observed that there were no changes in
these main peaks in the IR spectra of a mixture of drug and
polymers (Figures 2–4). The FTIR study revealed no physical
or chemical interactions of amoxicillin with sodium alginate
and HPMC K100 as evident from Figures 3 and 4.
4. Conclusion
Floating in situ gelling system of amoxicillin with increased
gastric residence time can be formulated using sodium8 ISRN Pharmaceutics
alginateasagellingpolymerandHPMCK100asathickening
agent. The prepared formulation can provide a site-speciﬁc
delivery of amoxicillin for 10 to 12h with zero-order release
kinetics.
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